AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$PTHS

Pauls Matthew sold $17K of PTHS

Pauls Matthew sold 786 shares of Pelthos Therapeutics Inc. (PTHS) at $21.00 on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pauls Matthew
Published Oct 6, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTHS
Neutral
high confidence
Mentioned
$PTHS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTHSNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential cumulative effect if multiple insiders sell in short period.

Relevance 2/10Novelty 2/10Timing: filing date Oct 6, 2026

Background

SEC Form 4 filing discloses insider transactions required by law.

Company-level read

Ticker impact

$PTHSNeutralHigh confidence
Context

Director Pauls Matthew sold 786 shares for $16,506 via a 10b5-1 plan on Oct 2, 2026.

Expected impact

possible modest downward pressure as market prices in the insider sale

Evidence & confidence

The transaction size is small relative to float and typical daily volume, limiting material impact.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

Limited to US biotech market perception.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

  • Company
    Pelthos Therapeutics Inc.

    Biotech firm listed on Nasdaq under ticker PTHS.

  • Individual
    Pauls Matthew

    Director of Pelthos Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTHS insider trading history →

Related articles

AUG 20
$PTHSHigh

Pelthos (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.

fool.com3 min
AUG 13
$PTHSMed

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescr

SEC EDGAR 8-K6 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min